References
- Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360–2.
- Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. A population-based estimate of corticosteroid dependence and resistance in ulcerative colitis. Gastroenterology 2001;120 Suppl 1:755.
- Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rugeerts P, et al. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn’s disease. Clin Immunol 2002;102:68–76.
- Sartor RS. Intestinal microflora in human and experimental IBD. Curr Opin GE 2001;17:324–30.
- Hanauer SB, Lichtenstein GR, Colombel JF, et al. Maintenance Infliximab (Remicade) is safe, effective and steroid-sparing in Crohn’s disease: preliminary results from the Accent I trial. Gastroenterology 2001;120 Suppl 1:99.
- The Antegren Publication Committee. A randomised, doubleblind, placebo-controlled, Pan-European study of a recombinant humanised antibody to α4 Integrin (Antegren) in moderate to severely active Crohn’s disease. Gastroenterology 2001; 120 Suppl 1:682.
- D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999;116:1029–34.
- Noman M, Baert F, D’Haens G, et al. HACA formation after infliximab (Remicade) treatment in Crohn’s disease is clearly associated with infusion reactions. Gastroenterology 2001;120 Suppl 1:3150.
- Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599–603.
- Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:603–6.
- Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachmimec C, et al. Probiotic bacteria enhance murine and human intestinal barrier function. Gastroenterology 2001;121: 580–91.
- Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622–35.
- Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354: 635–9.
- Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–8.
- Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–8.
- Gionchetti P, Rizzello F, Venturia A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305–9.
- Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997;25:653–8.
- Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462–4.